Atossa Therapeutics Announces First Patient Dosing of (Z)-En

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announced that the first patient has been dosed with Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (R

Related Keywords

California , United States , San Francisco , Eric Van Zanten , Nasdaq , University Of California , Atossa Therapeutics Inc , Selective Estrogen Receptor Modulator , Re Evaluating Conditions , Active Surveillance Suitability , Ductal Carcinoma In Situ , Carcinoma In Situ , Steven Quay , Chief Executive , Quantum Leap Healthcare Collaborative , Silicon Valley , Leap Healthcare Collaborative , Breast Cancer , Quantum Leap , Tossa , Active Surveillance , Iopharmaceutical Company , Atossa Therapeutics ,